Literature DB >> 19012814

Obsessive and compulsive symptoms in prediagnosed Huntington's disease.

Leigh J Beglinger1, Jane S Paulsen, David B Watson, Chiachi Wang, Kevin Duff, Douglas R Langbehn, David J Moser, Henry L Paulson, Elizabeth H Aylward, Noelle E Carlozzi, Sarah Queller, Julie C Stout.   

Abstract

OBJECTIVE: Obsessive and compulsive symptoms (OCS) are more prevalent in patients with diagnosed Huntington's disease (HD) than in the general population. Although psychiatric symptoms have been reported in individuals with the HD gene expansion prior to clinical diagnosis (pre-HD), little is known about OCS in this phase of disease.
METHOD: The goal of this study was to assess OCS in 300 pre-HD individuals and 108 non-gene-expanded controls from the Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study (enrolled between November 2002 and April 2007) using a multidimensional, self-report measure of OCS, the Schedule of Compulsions, Obsessions, and Pathologic Impulses (SCOPI). Additionally, pre-HD individuals were classified into 3 prognostic groups on the basis of age and CAG repeat length as "near-to-onset" (< 9 estimated years to onset), "mid-to-onset" (9-15 years to onset), and "far-to-onset" (> 15 years to onset). We compared the 3 pre-HD groups to the controls on SCOPI total score and 5 subscales (checking, cleanliness, compulsive rituals, hoarding, and pathologic impulses), controlling for age and gender.
RESULTS: All models showed a significant (p < .05) group effect except for hoarding, with an inverted-U pattern of increasing symptoms: controls < far-to-onset < mid-to-onset, with the near-to-onset group being similar to controls. Although the mid-to-onset group showed the most pathology, mean scores were below those of patients with diagnosed obsessive-compulsive disorder. SCOPI items that separated pre-HD individuals from controls were focused on perceived cognitive errors and obsessive worrying.
CONCLUSION: Subclinical OCS were present in pre-HD participants compared to controls. The OCS phenotype in pre-HD may present with obsessive worrying and checking related to cognitive errors and may be a useful target for clinical screening as it could contribute to functional status. Copyright 2008 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 19012814      PMCID: PMC3658314          DOI: 10.4088/jcp.v69n1111

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  33 in total

Review 1.  Huntington's disease and its association with psychopathology.

Authors:  N De Marchi; R Mennella
Journal:  Harv Rev Psychiatry       Date:  2000 Jan-Feb       Impact factor: 3.732

Review 2.  Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease.

Authors:  D Joel
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

3.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

4.  Critical periods of suicide risk in Huntington's disease.

Authors:  Jane S Paulsen; Karin Ferneyhough Hoth; Carissa Nehl; Laura Stierman
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

5.  Probability of obsessive and compulsive symptoms in Huntington's disease.

Authors:  Leigh J Beglinger; Douglas R Langbehn; Kevin Duff; Laura Stierman; Donald W Black; Carissa Nehl; Karen Anderson; Elizabeth Penziner; Jane S Paulsen
Journal:  Biol Psychiatry       Date:  2006-07-12       Impact factor: 13.382

6.  Symptoms of obsessive-compulsive disorder.

Authors:  J F Leckman; D E Grice; J Boardman; H Zhang; A Vitale; C Bondi; J Alsobrook; B S Peterson; D J Cohen; S A Rasmussen; W K Goodman; C J McDougle; D L Pauls
Journal:  Am J Psychiatry       Date:  1997-07       Impact factor: 18.112

7.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.

Authors:  E H Aylward; A M Codori; P E Barta; G D Pearlson; G J Harris; J Brandt
Journal:  Arch Neurol       Date:  1996-12

8.  The Zurich Study. XVIII. Obsessive-compulsive disorders and syndromes in the general population.

Authors:  M Degonda; M Wyss; J Angst
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

9.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

10.  Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders.

Authors:  L Baer
Journal:  J Clin Psychiatry       Date:  1994-03       Impact factor: 4.384

View more
  25 in total

1.  The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Authors:  Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Chiachi Wang; Julie C Stout; Christopher A Ross; Elizabeth Aylward; Noelle E Carlozzi; Sarah Queller
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

3.  Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Authors:  Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

4.  Self-reported strategies in decisions under risk: role of feedback, reasoning abilities, executive functions, short-term-memory, and working memory.

Authors:  Johannes Schiebener; Matthias Brand
Journal:  Cogn Process       Date:  2015-08-20

5.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

6.  Perceived stress in prodromal Huntington disease.

Authors:  Nancy Downing; Megan M Smith; Leigh J Beglinger; James Mills; Kevin Duff; Kelly C Rowe; Eric Epping; Jane S Paulsen
Journal:  Psychol Health       Date:  2011-06-21

7.  Suicidal ideation in Huntington disease: the role of comorbidity.

Authors:  Heather H Wetzel; Carissa R Gehl; Lisa Dellefave-Castillo; Judith F Schiffman; Kathleen M Shannon; Jane S Paulsen
Journal:  Psychiatry Res       Date:  2011-05-24       Impact factor: 3.222

8.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Authors:  Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker
Journal:  Lancet Neurol       Date:  2014-11-03       Impact factor: 44.182

9.  Patterns of serotonergic antidepressant usage in prodromal Huntington disease.

Authors:  Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Chiachi Wang; James Mills; Leigh J Beglinger; Megan M Smith; Eric A Epping; Jess G Fiedorowicz; Kevin Duff; Adam Ruggle; David J Moser
Journal:  Psychiatry Res       Date:  2012-03-05       Impact factor: 3.222

Review 10.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.